KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Pacira BioSciences (PCRX) Gross Profit (2016 - 2025)

Pacira BioSciences has reported Gross Profit over the past 16 years, most recently at $156.6 million for Q4 2025.

  • Quarterly results put Gross Profit at $156.6 million for Q4 2025, up 6.25% from a year ago — trailing twelve months through Dec 2025 was $576.7 million (up 8.69% YoY), and the annual figure for FY2025 was $576.7 million, up 8.69%.
  • Gross Profit for Q4 2025 was $156.6 million at Pacira BioSciences, up from $145.2 million in the prior quarter.
  • Over the last five years, Gross Profit for PCRX hit a ceiling of $156.6 million in Q4 2025 and a floor of -$554.1 million in Q4 2022.
  • Median Gross Profit over the past 5 years was $121.6 million (2022), compared with a mean of $90.1 million.
  • Biggest five-year swings in Gross Profit: tumbled 561.04% in 2022 and later surged 124.1% in 2023.
  • Pacira BioSciences' Gross Profit stood at $120.2 million in 2021, then tumbled by 561.04% to -$554.1 million in 2022, then soared by 124.1% to $133.6 million in 2023, then rose by 10.34% to $147.4 million in 2024, then grew by 6.25% to $156.6 million in 2025.
  • The last three reported values for Gross Profit were $156.6 million (Q4 2025), $145.2 million (Q3 2025), and $140.2 million (Q2 2025) per Business Quant data.